ARTICLE I DEFINITIONSLicense, Development and Supply Agreement • March 7th, 2003 • Imi International Medical Innovations Inc • Services-medical laboratories
LICENSE, DEVELOPMENT AND SUPPLY AGREEMENTLicense, Development and Supply Agreement • May 5th, 2006 • Antares Pharma Inc • Surgical & medical instruments & apparatus • Delaware
THIS LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT (the “Agreement”), dated as of November 23, 2005, (the “Effective Date”) entered into between SICOR PHARMACEUTICALS, INC., a Delaware corporation (“Teva / Sicor”), having a place of business located at 19 Hughes, Irvine, California 92618, and ANTARES PHARMA, INC., a Delaware corporation (“Antares”), having a place of business located at 707 Eagleview Boulevard, Suite 414, Exton, Pennsylvania 19341,
LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN McNEIL PDI Inc. (acting through its McNEIL Consumer Healthcare Division) a corporation existing under the laws of Canada AND McNEIL Consumer & Specialty Pharmaceuticals Division of McNEIL-PPC, Inc. a...License, Development and Supply Agreement • October 21st, 2004 • Imi International Medical Innovations Inc • Services-medical laboratories • New York
amount of Net Sales during such Fiscal Quarter and a calculation of the royalties due and such other information as called for in the format attached as Appendix L. McNEIL shall deliver the written report for each such Fiscal Quarter, regardless of whether when any royalties are required to be paid in that Fiscal Quarter, commencing in the first Fiscal Quarter following the date of the First Commercial Sale of any Product. Each such report shall state, separately for McNEIL and each Sublicensee, the number, description, and aggregate Net Sales, by country, of each Product sold during the Fiscal Quarter upon which a royalty is payable under this Agreement.
AMENDMENT TO LICENSE, DEVELOPMENT AND SUPPLY AGREEMENTLicense, Development and Supply Agreement • August 10th, 2006 • PreMD Inc. • Services-medical laboratories
LICENSE, DEVELOPMENT AND SUPPLY AGREEMENTLicense, Development and Supply Agreement • March 31st, 2023 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations
This License, Development and Supply Agreement (the “Agreement”) is entered into as of October 8, 2014 (the “Effective Date”) by and between Spectrum Pharmaceuticals inc., a Delaware corporation (“Spectrum”) and Hanmi Pharmaceuticals Co., Ltd., a company incorporated under the laws of the Republic of Korea (“Hanmi”).
AMENDMENT TO LICENSE, DEVELOPMENT AND SUPPLY AGREEMENTLicense, Development and Supply Agreement • May 12th, 2006 • PreMD Inc. • Services-medical laboratories
Portions of this Exhibit were omitted, as indicated by ********, and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN ALEXZA PHARMACEUTICALS, INC. and ENDO PHARMACEUTICALS INC.License, Development and Supply Agreement • March 17th, 2008 • Alexza Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT (this “Agreement”) is made and effective as of December 27, 2007 (the “Effective Date”) by and among Alexza Pharmaceuticals, Inc., a Delaware corporation (“Alexza”) and Endo Pharmaceuticals Inc., a Delaware corporation (“Endo”) (each of Alexza and Endo being a “Party,” and collectively, the “Parties”).
LICENSE, DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA ANDLicense, Development and Supply Agreement • November 7th, 2008 • Cv Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This License, Development and Supply Agreement is entered into and made effective as of the 12 th day of September, 2008 (“Effective Date”) by and between CV Therapeutics, Inc. a Delaware corporation having its principal place of business at 3172 Porter Drive, Palo Alto, California 94304, (“CVT”), and Menarini International Operation Luxembourg SA, a Luxembourg corporation, having its principal place of business at 1 Avenue de la Gare, L-1611, Luxembourg GD (“MIOL”). CVT and MIOL are each hereafter referred to individually as a “Party” and collectively as the Parties.
BUSINESS.29027546.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED....License, Development and Supply Agreement • May 4th, 2022 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • New York
LICENSE, DEVELOPMENT AND SUPPLY AGREEMENTLicense, Development and Supply Agreement • July 31st, 2006 • Viragen Inc • Biological products, (no disgnostic substances) • Delaware
This Agreement is made effective on 16th day of November, 2005 by and between Viragen Inc., a company incorporated in Delaware, USA with its principal offices located at 865 SW 78th Avenue, Plantation, Florida, USA, and its Affiliates and Subsidiaries (Viragen) and Kuhnil Pharm. Co., Ltd., a company incorporated in Seoul, Korea with its principal offices located at 237-12 Gong Deok-dong Mapo-gu and its Affiliates and Subsidiaries (Kuhnil);
AMENDMENT TO LICENSE, DEVELOPMENT AND SUPPLY AGREEMENTLicense, Development and Supply Agreement • August 10th, 2006 • PreMD Inc. • Services-medical laboratories
LICENSE, DEVELOPMENT, AND SUPPLY AGREEMENTLicense, Development, and Supply Agreement • August 6th, 2013 • Ontario
THIS AGREEMENT, effective July 5, 2013, by and between Bioniche Life Sciences Inc., a Canadian corporation, having its principal office at 231 Dundas Street East, Belleville, Ontario, Canada K8N 1E2 (“Bioniche”), Bioniche Therapeutics Corp., a wholly-owned subsidiary of Bioniche having its registered office at 231 Dundas Street East, Belleville, Ontario K8N 1E2 (“Bioniche Therapeutics”, and each of Bioniche and Bioniche Therapeutics acting either together or alone, “Bioniche”), and Paladin Labs Inc., a corporation incorporated under the laws of Canada having its principal office at 100 Blvd. Alexis Nihon, Suite 600, St-Laurent, Quebec H4M 2P2 (hereinafter, called “Paladin”).
AMENDMENT TO LICENSE, DEVELOPMENT AND SUPPLY AGREEMENTLicense, Development and Supply Agreement • May 12th, 2006 • PreMD Inc. • Services-medical laboratories
